<HTML><HEAD></HEAD><BODY>Global HIV Drugs Market to Exceed $15.5 Billion by 2015, According to New Report by Global Industry Analysts, Inc. | TradingMarkets.com  New ETF Book by Larry Connors Click here to read more
</br>
 Global HIV Drugs Market to Exceed $15.5 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
</br>
Posted on: Mon, 05 Apr 2010 12:01:09 EDT
</br>
, ,  Do you know when to trade  &  ?Check for a  from TradingMarkets  San Jose, CA, Apr 05, 2010 PRWeb.com via COMTEX Globally, prevalence of HIV continues to rise.As of 2008, an estimated 33.9 million people were surviving with this life threatening infection worldwide.The antiretroviral treatment aims at recovery from the damage caused by HIV.Anti retroviral treatment, called as post exposure prophylaxis, on early start after infection, can decrease the chances of infection.Globally, there is an increasing use of HAART or Highly Active Antiretroviral Therapy, which represent combinations involving minimum of 3 drugs related to 2 classes of antiretroviral agents.The United States dominates the global HIV drugs market as stated by the new market research report on HIV drugs http://www.strategyr.com/HIV_Drugs_Market_Report.asp market.Segment wise, Nucleoside Reverse Transcriptase Inhibitors http://www.strategyr.com/HIV_Drugs_Market_Report.asp represent the largest drug class in the global HIV drug market.Major drugs in this category include Ziagen, Retrovir, Hivid, Videx, Zerit, Epivir, Viread, and Combivir.NRTIs also represent the largest drug class in the US market.Other leading drugs in the market include Protease Inhibitors http://www.strategyr.com/HIV_Drugs_Market_Report.asp and Non Nucleoside Reverse Transcriptase Inhibitors.Key players profiled in the report include Abbott Laboratories, Boehringer Ingelheim GmbH, Bristol Myers Squibb Company, F. Hoffmann La Roche Ltd., Gilead Sciences, Inc., Merck & Co. Inc., Tibotec BVBA, ViiV Healthcare, VIRxSYS Corporation and Pharmacia & Upjohn LLC.The report titled "HIV Drugs: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of HIV disease, prevalence, incidence, drug categories, marketed drugs, pipeline drugs, growth drivers, drug approvals, and recent industry activity.The study analyzes market data and analytics in terms of value sales for regions including United States, Canada, Japan, Europe, and Rest of World.The study also provides analytics for the global and US markets by drug class NRTIs, NNRTIs, PIs and Others.For more details about this comprehensive market research report, please visit http://www.strategyr.com/HIV_Drugs_Market_Report.asp About Global Industry Analysts, Inc.Global Industry Analysts, Inc., GIA http://www.strategyR.com/ is a reputed publisher of off the shelf market research.Founded in 1987, the company is globally recognized as one of the world's largest market research publishers.The company employs over 800 people worldwide and publishes more than 1100 full scale research reports each year.Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.Global Industry Analysts, Inc. Telephone 408 528 9966 Fax 408 528 9977 Email press at StrategyR dot com Web Site http://www.StrategyR.com/ Read the full story at http://www.prweb.com/releases/HIV_drugs/antiretroviral_drugs/prweb3808724.htm.For full details on Bristol Myers Squibb Co BMY .Bristol Myers Squibb Co BMY has Short Term PowerRatings at TradingMarkets.Details on Bristol Myers Squibb Co BMY Short Term PowerRatings is available at For full details on Merck & Co MRK .Merck & Co MRK has Short Term PowerRatings at TradingMarkets.Details on Merck & Co MRK Short Term PowerRatings is available at For full details on Gilead Sciences Inc GILD .Gilead Sciences Inc GILD has Short Term PowerRatings at TradingMarkets.Details on Gilead Sciences Inc GILD Short Term PowerRatings is available at Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day.Join us for our  20 minute tele seminars during the week.Thursday April 29 12:30 PM Hear What Kevin Haggerty Sees in the Stock Market Today!Wednesday April 28 01:00 PM Hear What Gary Kaltbaum Sees in the Stock Market Today!* Attendance is strictly limited and are filled on a first come, first served basis. </br>
</BODY></HTML>